Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Cancer Cachexia Market?

In recent years, the market size for cancer cachexia has seen substantial growth. It is set to expand from a valuation of $2.47 billion in 2024 to $2.6 billion in 2025, portraying a compound annual growth rate (CAGR) of 5.3%. Factors such as enhanced knowledge of cancer biology, rising incidences of cancer, a growing elderly population, increased emphasis on patient-oriented care, a broader range of treatment choices, and increased cognizance among healthcare providers were integral to growth observed in the historical period.

The market for cancer cachexia is anticipated to experience robust expansion in the upcoming years, with expectations to reach $3.21 billion by 2029, rising at a compound annual growth rate (CAGR) of 5.5%. The predicted growth during the forecast period can be credited to the growing awareness about cachexia management, increasing geriatric population, the adoption of innovative treatment protocols, amplified health expenditure, and supportive initiatives by the government. Key trends projected for the forecast period include escalated research and development endeavors, augmentation of therapeutic solutions, enhancements in diagnosis rates, the uptake of pioneering treatment modalities, and advancements in accommodative care techniques.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

What Drivers Are Accelerating Expansion Of The Cancer Cachexia Market?

The growth of the cancer cachexia market is predicted to be driven by the rising incidences of cancer. This disease is characterized by abnormal cell proliferation, leading to tumor formation and interference with regular bodily activities. Factors contributing to cancer cases include lifestyle shifts, environmental influences, aging demographics, genetic susceptibility, superior diagnostics resulting in early detection, and heightened awareness, encouraging more individuals to seek medical consultation. Progress in medical technology and a deeper comprehension of cancer and its complications have led to greater diagnosis and recording of cancer cachexia. Healthcare workers are enhancing their proficiency in recognising cachexia symptoms, enabling prompt intervention and initiation of treatment. For example, in December 2023, the Australian Bureau of Statistics reported that approximately 1.8% of Australians or 456,200 individuals had been diagnosed with cancer in the previous year. Additionally, the National Cancer Institute estimated in May 2024, that there would be around 2,001,140 new cancer cases and 611,720 cancer-related deaths in the U.S. in 2024. In 2022, approximately 20 million fresh cases and 9.7 million deaths related to cancer were noted globally. By 2040, it is anticipated that the annual number of new cancer cases will increase to 29.9 million, and deaths due to cancer will reach 15.3 million. Consequently, the surge in cancer incidence is propelling the expansion of the cancer cachexia market.

What Are The Key Segment Trends Observed In The Cancer Cachexia Market?

The cancer cachexiamarket covered in this report is segmented –

1) By Therapeutics: Progestogens; Corticosteroids; Combination Therapies; Other Therapeutics

2) By Mechanism Of Action: Appetite Stimulators; Weight Loss Stabilizers; Other Mechanisms Of Actions

3) By Distribution Channel: Hospital Stores; Retail Pharmacy Stores; Online Pharmacies

Subsegments:

1) By Progestogens: Megestrol Acetate; Medroxyprogesterone Acetate; Hydroxyprogesterone Caproate

2) By Corticosteroids: Dexamethasone; Prednisolone; Methylprednisolone

3) By Combination Therapies: Progestogens + Corticosteroids; Progestogens + Anabolic Agents; Corticosteroids + Anabolic Agents

4) By Other Therapeutics: Anabolic Agents; Appetite Stimulants; Anti-inflammatory Drugs; Nutritional Supplements

What Strategic Shifts And Innovations Are Influencing The Cancer Cachexia Market?

Leading businesses in the cancer cachexia market are revolutionizing their approach by innovating new treatments such as monoclonal antibodies specifically for cachexia. Their goal is to create a focused solution for cancer cachexia to enhance body weight, muscle mass, and consequently, the overall life quality of the patients affected. These monoclonal antibodies specially designed for cachexia aim to counteract determinants that result in muscle deterioration and weight loss. For instance, US-based pharmaceutical giant, Pfizer Inc., declared the successful outcomes of their Phase 2 trial for Ponsegromab, a monoclonal antibody that targets GDF-15, in patients affected by cancer cachexia in September 2024. The study exhibited a notable rise in body weight, muscle mass, appetite, and physical activity levels, with the 400 mg dosage delivering the most powerful results. Given these encouraging results, Pfizer is planning to start initial enrollment studies in 2025 to further explore Ponsegromab’s potential in cancer cachexia treatment.

Who Are The Major Stakeholders Operating In The Cancer Cachexia Market?

Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

What Regional Factors Are Accelerating Growth In The Cancer Cachexia Market?

North America was the largest region in the cancer cachexia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Browse Through More Reports Similar to the Global Cancer Cachexia Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Bone Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bone-cancer-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model